logo-loader
viewScancell Holdings PLC

Scancell to work with Dutch firm on first product for Moditope cancer immuno-therapy platform

Dutch group ISA Pharmaceutical will incorporate its Amplivant technology into Modi-1, the first cancer treatment candidate being developed on the platform

Research Lab
Eventually, the collaboration might offer new treatments for triple negative breast cancer, ovarian, sarcomas and other solid tumours

Scancell Holdings PLC (LON:SCLP) saw its shares advance today after the firm agreed another collaborative development for its Moditope anti-cancer platform.

Dutch group ISA Pharmaceutical will incorporate its Amplivant technology into Modi-1, the first cancer treatment candidate being developed on the platform. Eventually, the collaboration might offer new treatments for triple negative breast cancer, ovarian, sarcomas and other solid tumours.

WATCH: New Scancell chief sets out his vision to commercialise groundbreaking cancer treatments

Scancell will make an (undisclosed) upfront payment in return for an exclusive worldwide licence to manufacture, develop and commercialise Amplivant:Modi-1.

Clinical studies are scheduled to start in the first half of 2019.

Moditope is an immunotherapy agent that acts to stimulate the production of killer CD4+ T cells, the body’s own defence against tumours.

Amplivant enables lower doses and improves efficacy by enabling the body to better recognise cancerous cells and attack them with T cells.

Cliff Holloway, Scancell’s chief executive, said working with ISA was an important first step towards commercialising the Moditope immunotherapy, Modi-1.

READ: Scancell to receive patent protection for key cancer platform

“Our pre-clinical studies have demonstrated Modi-1 induces potent anti-tumour responses and significant improvements in survival”.

“We believe that combining Modi-1 with an enabling adjuvant technology such as Amplivant has the potential to significantly enhance its efficacy in patients.”

Ronald Loggers, ISA’s chief executive, added: "The partnership will further validate the power of Amplivant conjugates for use in therapeutic cancer vaccines."

Last year, Scancell agreed a Moditope collaboration with another European firm, BioNTech for high-throughput cloning and characterisation of naturally selected T-cell receptors.

In late afternoon trading, Scancell shares were up 12% at 140.

 -- Adds share price --

Quick facts: Scancell Holdings PLC

Price: 5.09 GBX

LSE:SCLP
Market: LSE
Market Cap: £23.69 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibody collaboration deal for Scancell

Scancell Holdings (LON:SCLP) has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly. CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing...

on 5/9/19

2 min read